Co-Diagnostics Past Earnings Performance

Past criteria checks 2/6

Co-Diagnostics has been growing earnings at an average annual rate of 64.5%, while the Medical Equipment industry saw earnings growing at 4.2% annually. Revenues have been growing at an average rate of 71.7% per year. Co-Diagnostics's return on equity is 19.4%, and it has net margins of 35.8%.

Key information

64.5%

Earnings growth rate

62.2%

EPS growth rate

Medical Equipment Industry Growth4.3%
Revenue growth rate71.7%
Return on equity19.4%
Net Margin35.8%
Next Earnings Update10 Nov 2022

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Co-Diagnostics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

MUN:C97 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2278282216
31 Mar 22101402617
31 Dec 2198372515
30 Sep 21105422514
30 Jun 219646219
31 Mar 219351155
31 Dec 207542133
30 Sep 20482892
30 Jun 20261072
31 Mar 202-651
31 Dec 190-651
30 Sep 190-651
30 Jun 190-651
31 Mar 190-651
31 Dec 180-651
30 Sep 180-651
30 Jun 180-851
31 Mar 180-841
31 Dec 170-741
30 Sep 170-631
30 Jun 170-311
31 Mar 170-211
31 Dec 160-211
30 Sep 160-211
31 Dec 150-211

Quality Earnings: C97 has high quality earnings.

Growing Profit Margin: C97's current net profit margins (35.8%) are lower than last year (48%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: C97 has become profitable over the past 5 years, growing earnings by 64.5% per year.

Accelerating Growth: C97's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: C97 had negative earnings growth (-39.4%) over the past year, making it difficult to compare to the Medical Equipment industry average (3.3%).


Return on Equity

High ROE: C97's Return on Equity (19.4%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/11/09 16:30
End of Day Share Price 2022/08/12 00:00
Earnings2022/06/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Co-Diagnostics, Inc. is covered by 2 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yi ChenH.C. Wainwright & Co.
James SidotiSidoti & Company, LLC